5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2

Differentiation

Volumn 74, Issue 9-10, 2006, Pages 488-498

  Strasser, Stephen ^a   Maier, Susanne ^a   Leisser, Christina ^a   Saiko, Philipp ^a   Madlener, Sibylle ^a   Bader, Yvonne ^a   Bernhaus, Astrid ^a   Gueorguieva, Marieta ^b   Richter, Susanne ^b   Mader, Robert M ^a   Wesierska Gadek, Jozefa ^b   Schott, Herbert ^c   Szekeres, Thomas ^a   Fritzer Szekeres, Monika ^a   Krupitza, Georg ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

5 FdUrd araC; Apoptosis; Chemoresistance; erbB2; Proliferation

Indexed keywords

5 FLUORO 2' DESOXYURIDYLYL(3'-5')ARABINOCYTIDINE; APOPTOSIS INDUCING FACTOR; CASPASE 7; CYCLIN D1; CYTARABINE; DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLOXURIDINE; NUCLEOSIDE DERIVATIVE; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 33845516415     PISSN: 03014681     EISSN: 14320436     Source Type: Journal    
DOI: 10.1111/j.1432-0436.2006.00082.x     Document Type: Article

References (26)

1. Agarwal, R.P., Han, T. and Fernandez, M. (2001) Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance. Biochem Pharmacol 61:39-47.
2. Bhalla, K., Nayak, R. and Grant, S. (1984) Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D-arabinofuranosylcytosine. Cancer Res 44:5029-5037.
3. Blum, J.L., Jones, S.E., Buzdar, A.U., LoRusso, P.M., Kuter, I., Vogel, C., Osterwalder, B., Burger, H.U., Brown, C.S. and Griffin, T. (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493.
4. Cande, C., Cecconi, F., Dessen, P. and Kroemer, G. (2002) Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death? J Cell Sci 115:4727-4734.
5. Cattaneo-Pangrazzi, R.M., Schott, H. and Schwendener, R.A. (2000) The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145. The Prostate 45:8-18.
6. Cragg, G.M. and Newman, D.J. (2000) Antineoplastic agents from natural sources: achievements and future directions. Expert Opin Investig Drugs 9:2783-2797.
7. Early, A.P., Preisler, H.D., Slocum, H. and Rustum, Y.M. (1982) A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res 42:1587-1594.
8. Germain, M., Affar, E.B., D'Amours, D., Dixit, V.M., Salvesen, G.S. and Poirier, G.G. (1999) Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7. J Biol Chem 274:28379-28384.
9. Grusch, M., Polgar, D., Gfatter, S., Leuhuber, K., Huettenbrenner, S., Leisser, C., Fuhrmann, G., Kassie, F., Steinkellner, H., Smid, K., Peters, G.J., Jayaram, H.N., Klepal, W., Szekeres, T., Knasmuller, S. and Krupitza, G. (2002) Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside. Cell Death Differ 9:169-178.
10. Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell 100:57-70.
11. Huettenbrenner, S., Maier, S., Leisser, C., Polgar, D., Strasser, S., Grusch, M. and Krupitza, G. (2003) The evolution of cell death programs as prerequisites of multicellularity. Mutat Res 543:235-249.
12. Kottke, T.J., Blajeski, A.L., Meng, X.W., Svingen, P.A., Ruchaud, S., Mesner, P.W. Jr., Boerner, S.A., Samejima, K., Henriquez, N.V., Chilcote, T.J., Lord, J., Salmon, M., Earnshaw, W.C. and Kaufmann, S.H. (2002) Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells. J Biol Chem 277:804-815.
13. Maier, S., Strasser, S., Saiko, P., Leisser, C., Sasgary, S., Grusch, M., Madlener, S., Bader, Y., Hartmann, J., Schott, H., Mader, R.M., Szekeres, T., Fritzer-Szekeres, M. and Krupitza, G. (2006) Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC. Apoptosis 11:427-440.
14. Momparler, R.L. (1974) A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine. Cancer Res 34:1775-1787.
15. Oshaughnessy, J.A., Blum, J., Moiseyenko, V., Jones, S.E., Miles, D., Bell, D., Rosso, R., Mauriac, L., Osterwalder, B., Burger, H.U. and Laws, S. (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247-1254.
16. Pianetti, S., Arsura, M., Romieu-Mourez, R., Coffey, R.J. and Sonenshein, G.E. (2001) Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20:1287-1299.
17. Romieu-Mourez, R., Landesman-Bollag, E., Seldin, D.C. and Sonenshein, G.E. (2002) Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res 62:6770-6778.
18. Saiko, P., Horvath, Z., Illmer, C., Madlener, S., Bauer, W., Hoechtl, T., Erlach, N., Grusch, M., Krupitza, G., Mader, R.M., Jaeger, W., Schott, H., Agarwal, R.P., Fritzer-Szekeres, M. and Szekeres, T. (2005) Cytotoxic effects of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine in cross-resistant H9 human lymphoma cells. Leuk Res 29:785-791.
19. Stehlik, C., de Martin, R., Kumabashiri, I., Schmid, J.A., Binder, B.R. and Lipp, J. (1998) Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 188:211-216.
20. Susin, S.A., Lorenzo, H.K., Zamzami, N., Marzo, I., Snow, B.E., Brothers, G.M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., Larochette, N., Goodlett, D.R., Aebersold, R., Siderovski, D.P., Penninger, J.M. and Kroemer, G. (1999) Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397:441-446.
21. Szekeres, T., Schuchter, K., Chiba, P., Ressmann, G., Lhotka, C., Gharehbaghi, K., Szalay, S.M. and Pillwein, K. (1993) Synergistic action of tiazofurin with hypoxanthine and allopurinol in human neuroectodermal tumor cell lines. Biochem Pharmacol 46:1903-1907.
22. Talbot, D.C., Moiseyenko, V., Van Belle, S., O'Reilly, S.M., Alba Conejo, E., Ackland, S., Eisenberg, P., Melnychuk, D., Pienkowski, T., Burger, H.U., Laws, S. and Osterwalder, B. (2002) Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86:1367-1372.
23. Weinstein, J.N., Myers, T.G., O'Connor, P.M., Friend, S.H., Fornace, A.J. Jr., Kohn, K.W., Fojo, T., Bates, S.E., Rubinstein, L.V., Anderson, N.L., Buolamwini, J.K., van Osdol, W.W., Monks, A.P., Scudiero, D.A., Sausville, E.A., Zaharevitz, D.W., Bunow, B., Viswanadhan, V.N., Johnson, G.S., Wittes, R.E. and Paull, K.D. (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275:343-349.
24. Wilkinson, D.S. and Crumley, J. (1977) Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells. J Biol Chem 252:1051-1056.
25. Yu, D. (2001) Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol 28:12-17.
26. Yu, D. and Hung, M.C. (2000) Role of erbB2 in breast cancer chemosensitivity. Bioessays 22:673-680.